ABSTRACT
Aim: Investigations have shown that for the antibody-drug conjugate (ADC) belantamab mafodotin, concentrations of the cysteine-conjugated metabolite, Cys-mcMMAF, were overestimated in the presence of the ADC during sample processing when utilizing a historical SPE method. Results: A new assay was developed utilizing an acidic protein precipitation to remove the ADC early in the extraction process, thus eliminating the risk of overestimating Cys-mcMMAF in the presence of belantamab mafodotin. In vitro experiments demonstrated a linear relationship between the concentration of belantamab mafodotin and the release of Cys-mcMMAF. Extensive stability assessments were performed to cover storage of study samples. Conclusion: This work emphasized the critical importance of understanding the performance of a bioanalytical method for free toxic payload in the presence of the ADC.
ABSTRACT
BACKGROUND: FTIH studies can be challenging due to the varying dosing regimens and rapid data delivery. Chemists are asked to provide ultra-low limits of quantitation to provide an understanding of patient efficacy and safety in order to progress drug development. In a recent dermal study it became necessary to reduce the LLOQ of a small molecule drug from 50 to 1 pg/ml due to reductions in the dose and surface area of drug application. METHODOLOGY: The 50-fold increase in assay sensitivity necessitated the use of a high-resolution mass spectrometer (LC-HRMS) to separate matrix interferences observed when using a unit resolution triple quadrupole MS. CONCLUSION: A sensitive, robust assay was validated to support of a FTIH study using a LC-HRMS.
Subject(s)
Blood Chemical Analysis/methods , Limit of Detection , Mass Spectrometry/methods , Skin , Small Molecule Libraries/analysis , Chromatography, Liquid , Healthy Volunteers , Humans , Reproducibility of Results , Small Molecule Libraries/chemistry , Tandem Mass SpectrometryABSTRACT
BACKGROUND: Domain antibodies (dAbs; â¼10-15 kDa) are made up of the variable heavy chain or the variable light chain of the antibody structure, and retain binding capability. dAbs have proved difficult to detect in plasma using immunoassay without specific antibodies raised against the dAb. RESULTS: A sensitive and selective UPLC-MS/MS method for the absolute quantification of a dAb in monkey plasma was developed (range: 1 to 500 ng/ml) without the need for a specific capture antibody. This method was used to analyze pharmacokinetic studies early on in drug development. Furthermore, an immunoassay was developed and the pharmacokinetic samples were reanalyzed. CONCLUSION: The two assays show good correlation (r(2) = 0.92), giving confidence in using either method for quantification of the dAb.
Subject(s)
Blood Chemical Analysis/methods , Chromatography, High Pressure Liquid/methods , Immunoassay/methods , Immunoglobulin Fragments/blood , Tandem Mass Spectrometry/methods , Administration, Inhalation , Animals , Immunoglobulin Fragments/administration & dosage , Immunoglobulin Fragments/metabolism , Immunoglobulin Fragments/therapeutic use , Immunoglobulin G/chemistry , Immunoglobulin G/immunology , Injections, Intravenous , Macaca fascicularis , Trypsin/metabolismABSTRACT
BACKGROUND: An investigation was performed in order to establish if dried blood spots (DBS) could be applied to the quantitation of biopharmaceuticals in biological matrices and perform equivalently in terms of accuracy, precision and stability to traditional plasma methods. RESULTS: A method was successfully validated for the peptide Exendin-4 (39 amino acids in length) utilizing DBS technology. The validated DBS method resulted in a more sensitive and simplistic method than an existing monkey plasma method and required tenfold less sample volume. The final DBS method resulted in a 10-2000-ng/ml linear calibration range using approximately 5 µl of dried blood, compared with the plasma method in which 150 µl of plasma coupled with SPE sample preparation resulted in a 20-2000-ng/ml linear calibration range. Although not needed for DBS, SPE was required for the plasma method to reduce endogenous matrix interferences and achieve desired LLOQ. Matrix stability was also enhanced by the implementation of the DBS platform when compared with either plasma or whole blood. CONCLUSION: DBS technology can be utilized for the quantitation of biopharmaceuticals and offer advantages over traditional plasma-based methods.
